FibroGen Performance
| FGENDelisted Stock | USD 9.71 0.69 7.65% |
The firm shows a Beta (market volatility) of 0.31, which means possible diversification benefits within a given portfolio. As returns on the market increase, FibroGen's returns are expected to increase less than the market. However, during the bear market, the loss of holding FibroGen is expected to be smaller as well. At this point, FibroGen has a negative expected return of -0.12%. Please make sure to confirm FibroGen's jensen alpha, accumulation distribution, relative strength index, as well as the relationship between the value at risk and day typical price , to decide if FibroGen performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days FibroGen has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's technical and fundamental indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
1 | How to read the order book for FibroGen Inc. - July 2025 Price Swings Verified Momentum Stock Alerts - newser.com | 10/13/2025 |
2 | Will FibroGen Inc. stock keep raising dividends - July 2025 PostEarnings Risk Managed Trade Strategies - fcp.pa.gov.br | 11/05/2025 |
3 | FibroGen Q3 Earnings Snapshot | 11/10/2025 |
4 | FibroGen Inc Q3 2025 Earnings Call Highlights Strategic Moves Bolster Financial ... | 11/11/2025 |
5 | FibroGen, Inc. Q3 2025 Earnings Call Transcript | 11/12/2025 |
6 | Acquisition by Thane Wettig of 2700 shares of FibroGen at 9.0999 subject to Rule 16b-3 | 11/17/2025 |
7 | UCSF buys former biotech headquarters in Mission Bay expansion | 12/17/2025 |
| Begin Period Cash Flow | 113.7 M | |
| Total Cashflows From Investing Activities | 126 M |
FibroGen |
FibroGen Relative Risk vs. Return Landscape
If you would invest 1,097 in FibroGen on October 11, 2025 and sell it today you would lose (126.00) from holding FibroGen or give up 11.49% of portfolio value over 90 days. FibroGen is currently does not generate positive expected returns and assumes 4.1366% risk (volatility on return distribution) over the 90 days horizon. In different words, 37% of stocks are less volatile than FibroGen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
FibroGen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for FibroGen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as FibroGen, and traders can use it to determine the average amount a FibroGen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0286
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FGEN |
Based on monthly moving average FibroGen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of FibroGen by adding FibroGen to a well-diversified portfolio.
FibroGen Fundamentals Growth
FibroGen Stock prices reflect investors' perceptions of the future prospects and financial health of FibroGen, and FibroGen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on FibroGen Stock performance.
| Return On Equity | -10.16 | |||
| Return On Asset | -0.18 | |||
| Profit Margin | 25.99 % | |||
| Operating Margin | (4.99) % | |||
| Current Valuation | 86.86 M | |||
| Shares Outstanding | 4.05 M | |||
| Price To Earning | 97.67 X | |||
| Price To Book | 53.83 X | |||
| Price To Sales | 4.40 X | |||
| Revenue | 29.62 M | |||
| EBITDA | (142.43 M) | |||
| Cash And Equivalents | 438.13 M | |||
| Cash Per Share | 4.67 X | |||
| Total Debt | 90.17 M | |||
| Debt To Equity | 0.89 % | |||
| Book Value Per Share | (4.21) X | |||
| Cash Flow From Operations | (138 M) | |||
| Earnings Per Share | (12.85) X | |||
| Total Asset | 214.53 M | |||
| Retained Earnings | (1.89 B) | |||
| Current Asset | 200.56 M | |||
| Current Liabilities | 67.18 M | |||
About FibroGen Performance
By examining FibroGen's fundamental ratios, stakeholders can obtain critical insights into FibroGen's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that FibroGen is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Fibrogen Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 566 people.Things to note about FibroGen performance evaluation
Checking the ongoing alerts about FibroGen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for FibroGen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| FibroGen is now traded under the symbol KYNB. Please update your portfolios or report it if you believe this is an error. Report It! | |
| FibroGen generated a negative expected return over the last 90 days | |
| FibroGen has high historical volatility and very poor performance | |
| FibroGen has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 29.62 M. Net Loss for the year was (47.58 M) with loss before overhead, payroll, taxes, and interest of (30.35 M). | |
| FibroGen currently holds about 438.13 M in cash with (138 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.67. | |
| Latest headline from finance.yahoo.com: UCSF buys former biotech headquarters in Mission Bay expansion |
- Analyzing FibroGen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether FibroGen's stock is overvalued or undervalued compared to its peers.
- Examining FibroGen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating FibroGen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of FibroGen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of FibroGen's stock. These opinions can provide insight into FibroGen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in FibroGen Stock
If you are still planning to invest in FibroGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the FibroGen's history and understand the potential risks before investing.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |